SPECIAL FEATURES

**CCR Pediatric Oncology Series**

Complimentary access to this online-only series of articles from the AACR Childhood Cancer Predisposition Workshop:
clinicancerres.aacrjournals.org/pediatricseries

**e46** Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1
D. Gareth R. Evans, Hector Salvador, Vivian Y. Chang, Ayelet Erez, Stephan D. Voss, Kami Wolfe Schneider, Hamish S. Scott, Sharon E. Plon, and Uri Tabori

**e54** Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders

**e62** Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome
William D. Foulkes, Junne Kamihara, D. Gareth R. Evans, Laurence Brugieres, Franck Bourdeaut, Ian J. Molenaar, Michael F. Walsh, Garrett M. Brodeur, and Lisa Diller

**e68** Von Hippel–Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood

**e76** PTEN, DICER1, FH, and Their Associated Tumor Susceptibility Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood
Kris Ann P. Schultz, Surya P. Rednam, Junne Kamihara, Leslie Doros, Maria Isabel Achatz, Jonathan D. Wasserman, Lisa R. Diller, Laurence Brugieres, Harriet Druker, Katherine A. Schneider, Rose B. McGee, and William D. Foulkes

**e83** Recommendations for Cancer Surveillance in Individuals with RASopathies and Other Rare Genetic Conditions with Increased Cancer Risk
Anita Villani, Mary-Louise C. Greer, Jennifer M. Kalish, Akira Nakagawa, Katherine L. Nathanson, Kristian W. Pajtler, Stefan M. Pfister, Michael F. Walsh, Jonathan D. Wasserman, Kristin Zelley, and Christian P. Kratz

Highlights of This Issue 2919

**CCR Translations**

**2921** The "Tricky Business" of Identifying Mechanisms of Resistance to Anti–PD-1
James S. Wilcott, Helen Rizos, Richard A. Scolyer, and Georgina V. Long
See related article, p. 3168

**CCR Drug Updates**

**2924** FDA Approval Summary: TAS-102
Leigh Marcus, Steven J. Lemery, Sachia Khasar, Emily Wearne, Whitney S. Helms, Weishui Yuan, Kun He, Xianhua Cao, Jingyu Yu, Hong Zhao, Yaning Wang, Olen Stephens, Erika Englund, Rajiv Agarwal, Patricia Keegan, and Richard Pazdur

**Molecular Pathways**

**2928** Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion—A New Role for the AXL Receptor Tyrosine Kinase
Todd A. Aguilera and Amato J. Giaccia

**2934** Molecular Pathways: Evaluating the Potential for B7-H4 as an Immunoregulatory Target
Heather L. MacGregor and Pamela S. Ohashi

**CANCER THERAPY: CLINICAL**

**2942** Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody
George A. Dominguez, Thomas Condamine, Sridevi Mony, Ayumi Hashimoto, Fang Wang, Qin Liu, Andres Forero, Johanna Bendell, Robert Witt, Neil Hockstein, Prasanna Kumar, and Dmitry I. Gabrilovich

**2951** Neural Stem Cell–Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent High-Grade Glioma Patients
2961 Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial
Lea Lowenfeld, Rosemarie Mick, Jashodeep Datta, Shuwen Xu, Elizabeth Fitzpatrick, Carla S. Fisher, Kevin R. Fox, Angela DeMichele, Paul I. Zhang, Susan P. Weinstein, Robert E. Roses, and Brian J. Czerniecki

2972 Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab
Sandra P. D’Angelo, Alexander N. Shoushtari, Mary Louise Krohan, Mark A. Dickson, Minral M. Gounder, Ping Chi, Jennifer K. Loo, Leigh Gaffney, Lee Schneider, Zarine Patel, Joseph Patrick Erinjeri, Mark J. Bluth, Ana Sjoberg, Howard Streicher, Naoko Takebe, Li-Xuan Qin, Cristina Antonescu, Ronald P. DeMatteo, and William D. Tap

2981 Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations
Gang G. Li, Romel Somwar, James Joseph, Roger S. Smith, Takuo Hayashi, Leenus Martin, Aleksandra Franovic, Anni Schaier, Eric Martin, Gregory J. Riely, Jason Harris, Shunqi Yan, Ge Wei, Jennifer W. Oliver, Rupal Patel, Pratik Multani, Marc Ladanyi, and Alexander Drilon

2991 Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer
Kelly K. Hunt, Cansu Karakas, Min Jin Ha, Anna Biernacka, Min Yi, Aysegul A. Sahin, Opoku Adajpong, Gabriel N. Hortobagyi, Melissa L. Bondy, Patricia A. Thompson, Kwok Leung Cheung, Ian O. Ellis, Sarah Baccus, W. Fraser Symmans, Kim-Anh Do, and Khandan Keyomarsi

3003 A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations: Observations from a Randomized Co-Endpoint Trial HCRN 12-157
Noah M. Hahn, Trinity J. Bivalacqua, Ashley E. Ross, John C. Truillet, Matthew F.L. Parker, Loc T. Huynh, Crystal S. Conn, Davide Ruggero, Jason S. Lewis, and Michael J. Evans

3012 Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong-Yi Dong, Wen-Zhao Zhong, Xu-Chao Zhang, Jian Su, Zhi Xie, Si-Yang Liu, Hai-Yan Tu, Hua-Jun Chen, Yue-Li Sun, Qing Zhou, Jin-Ji Yang, Yue-Ning Yang, Jia-Xin Lin, Hong-Hong Yan, Hao-Ran Zhai, Li-Xuan Qin, Ri-Qiang Liao, Si-Pei Wu, and Yi-Long Wu
CANCER THERAPY: PRECLINICAL

3061 Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues

3072 Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients
Toni M. Brand, Stefan Hartmann, Neil E. Bhola, Noah D. Peyser, Hua Li, Yan Zeng, Erin Isaacson Wechsler, Max V. Ranall, Sourav Bandyopadhyay, Unnامahenwar Duvvuri, Theresa M. LaVallee, Richard C.K. Jordan, Daniel E. Johnson, and Jennifer R. Grandis

3084 Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib
Jennifer E. Amengual, Sathyen A. Prabhu, Maximilian Lombardo, Kelly Zullo, Paul M. Johannet, Yuilissa Gonzalez, Luigi Scoito, Xavier Iraz Serrano, Ying Wei, Jimmy Duong, Renu Nandakumar, Serge Cremer, Akanksha Verma, Olivier Elemento, and Owen A. O’Connor

3097 Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models
Hyoung Kim, Erin George, Ryan L. Ragland, Stavros Rafail, Rungang Zhang, Clemens Krepler, Mark A. Morgan, Meenhard Herlyn, Eric J. Brown, and Fiona Simpkins

3109 Malignant Astrocytic Tumor Progression Potentiated by JAK-mediated Recruitment of Myeloid Cells
Prajwal Rajappa, William S. Cobb, Emma Vartanian, Yue Huang, Laura Daly, Caitlin Hoffman, Jane Zhang, Beiyi Shen, Rachel Yanowitch, Kunal Garg, Babacar Cisse, Sara Haddock, Jason Huse, David J. Pispia, Timothy A. Chan, David C. Lyden, Jacqueline F. Bromberg, and Jeffrey P. Greenfield

BIOLOGY OF HUMAN TUMORS

3120 Involvement of c-Fos in the Promotion of Cancer Stem-like Cell Properties in Head and Neck Squamous Cell Carcinoma
Naoshad Muhammad, Sourav Bhattacharya, Robert Steele, Nancy Phillips, and Ratna B. Ray

3129 Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer
David Balli, Andrew J. Rech, Ben Z. Stanger, and Robert H. Vonderheide

3139 Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer
Azusa Tanimoto, Shinji Takeuchi, Sachiko Arai, Koji Fukuda, Tadaaki Yamada, Xavier Roca, S. Tiong Ong, and Seiji Yano

3150 Absence of Cytomegalovirus in Glioblastoma and Other High-grade Gliomas by Real-time PCR, Immunohistochemistry, and In Situ Hybridization
Matthias Holdhoff, Gunes Guner, Fausto J. Rodriguez, Jessica L. Hicks, Qizhi Zheng, Michael S. Forman, Xiaobu Ye, Stuart A. Grossman, Alan K. Meeker, Christopher M. Heaphy, Charles G. Eberhart, Angelo M. De Marzo, and Ravit Arav-Roger

3158 PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
Jennifer H. Yearley, Christopher Gibson, Ni Yu, Christina Moon, Erin Murphy, Jonathan J. Luco, Jared Lanceford, Jonathan Cheng, Laura Q.M. Chow, Tangry Seiwert, Masahisa Handa, Joanne E. Tomassini, and Terrill McClanahan

3168 Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy

See related commentary, p. 2921

3181 Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho
Reteti Behera, Amanpreet Kaur, Marie R. Webster, Suyeon Kim, Aribatou N’doye, Curtis H. Kugel III, Gretchen M. Alicea, Joshua Wang, Kanad Ghosh, Phil Cheng, Sofia Lisanti, Katie Marchbank, Vanessa Dang, Mitchell Levesque, Reinhard Dummer, Xiaowei Xu, Meenhard Herlyn, Andrew E. Aplin, Alexander Roessch, Cecilia Caino, Dario C. Altieri, and Ashani T. Weeraratna
LETTERS TO THE EDITOR

3223 Inhibitor of Pancreatic Cancer by RHIL1RA—Letter
Sinan Lu, Shusen Zheng, and Weilin Wang

3224 Inhibition of Pancreatic Cancer by RHIL1RA—Response
Paul J. Chiao, Jianhua Ling, Jie Fu, Yu Lu, and Yi-Chen Sun

CORRECTIONS

3225 Correction: Frequent Overexpression of HMGA2 in Human Atypical Teratoid/Rhabdoid Tumor and Its Correlation with let-7a3/let-7b miRNA

3226 Correction: Indole-3-Carbinol Synergizes with and Restores Fludarabine Sensitivity in Chronic Lymphocytic Leukemia Cells Irrespective of p53 Activity and Treatment Resistances
ABOUT THE COVER

The cover shows a section of an oropharynx tumor from a patient with HPV-associated head and neck cancer. Immunohistochemical staining shows strong membranous HER3 expression in a small area of the tumor. For details, see the article by Brand and colleagues on page 3072 of this issue.
Clinical Cancer Research

23 (12)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/23/12

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.